Patent ID: 9688657
Date: 2017-06-27
CPC Classifications: C07C,C07D

Claim:
1. A process for preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof, comprising the steps of, a) treating Ethyl-3-{[(2-formyl-1-methyl-1H-benzimidazole-5-yl)carbonyl]-(2-pyridinyl)amino}propanoate with 4-aminobenzamidine or N-hydroxy-4-aminobenzamidine in presence of a reducing agent to obtain 1-methyl-2-[N-[4-amidinophenyl]aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonyl ethyl)amide; b) optionally purifying said 1-methyl-2-[N-[4-amidinophenyl]aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxy carbonyl ethyl)amide; c) converting said 1-methyl-2-[N-[4-amidinophenyl]aminomethyl]benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonyl ethyl)amide to Dabigatran etexilate or pharmaceutically acceptable salt thereof.